Camurus (OM:CAMX) Stock Faces Margin Slip As Q2 Net Profitability Pressures Bull Case

Camurus (OM:CAMX) has put solid numbers on the table for Q2 2026, with revenue of SEK702.1 million and basic EPS of SEK4.05, backed by trailing twelve month revenue of SEK2.3 billion and EPS of SEK11.38. Over the past few quarters, the company has seen revenue move from SEK558.3 million and EPS of SEK3.36 in Q1 2025 to SEK533.1 million and EPS of SEK2.42 in Q1 2026, before reaching the latest Q2 levels. With a trailing net profit margin of 29.9% and a track record of turning EPS into meaningful net income, the latest release puts the focus squarely on how sustainable these margins look from here.

See our full analysis for Camurus.

With the headline figures in place, the next step is to set these results against the main market narratives around Camurus to see which stories the numbers back up and which they call into question.

See what the community is saying about Camurus

Camurus margin profile shows a small step down

• On a trailing basis, Camurus is converting SEK2,266.7 million of revenue into SEK678.2 million of net income, which equates to a 29.9% net margin compared with 31.7% in the prior year period mentioned in the analysis.
• Bears point to this margin slip as a sign that pricing and cost pressures could build over time. However, the latest quarterly figures of SEK702.1 million revenue and SEK240.8 million net income still sit alongside high reported gross profitability and a debt free position, which challenges the idea that earnings quality is already being structurally squeezed.
  • The bearish narrative highlights risks from tighter price controls and potential generic competition, but the current 29.9% margin on the trailing numbers remains well above what many pharma companies achieve once they hit maturity.
  • Critics also flag dependence on a narrow set of drugs. At the same time, the presence of multiple late stage products, including Phase III and pre registration assets in earlier quarters, shows management has already been investing to broaden the earnings base.

For readers weighing whether the recent earnings support the more optimistic case that some investors see, it is worth stepping through the full bull thesis in detail 🐂 Camurus Bull Case.

Valuation tension at SEK639 share price

• At a share price of SEK639, Camurus trades on a 56.1x P/E in the analysis data, which is lower than the peer group average of 79.5x but higher than the wider European pharmaceuticals average of 20.7x. A DCF fair value of SEK1,337.18 and an analyst target of SEK776.75 both sit above the current price.
• Bears focus on the stock looking expensive versus the broader industry. However, the combination of a DCF fair value that is more than SEK600 above the share price and analyst forecasts for revenue growth of 27.4% per year and earnings growth of 34.35% per year gives bulls numerical backing for arguing that the current multiple already bakes in some caution.
  • Consensus commentary in the analysis notes that Camurus is profitable on SEK678.2 million of trailing net income, which can make a higher P/E easier to justify than for early stage peers that are still loss making.
  • At the same time, the mixed picture where Camurus is cheaper than its immediate peer set but richer than the regional industry average is exactly what keeps valuation debates active between bullish and bearish investors.

Skeptical readers who are more focused on the cautious side of the story may want to see how bearish analysts connect these valuation numbers to their concerns 🐻 Camurus Bear Case.

Growth track record meets forecast optimism

• Over the last five years, the analysis shows Camurus shifting from loss making into profitability with historical earnings growth of 53.8% per year. Looking ahead, the same dataset points to forecast revenue growth of 27.4% per year and earnings growth of 34.35% per year on top of current trailing EPS of SEK11.38.
• Supporters of the bullish narrative argue that expanding use of long acting treatments and partnerships in areas like cardiometabolic disease could justify those growth forecasts. The move from SEK547.8 million of trailing net income in early 2025 to SEK678.2 million in the latest trailing period illustrates why they see Camurus as already translating its pipeline and launches into higher earnings rather than relying purely on story.
  • The bullish view leans on strong demand for products that improve treatment adherence, which is consistent with the data showing Camurus generating over SEK2.2b of trailing revenue while maintaining a near 30% net margin.
  • At the same time, the analysis flags a small margin decline and negative single year earnings change in the most recent trailing period, giving cautious investors concrete figures to watch as they assess how much of the bullish growth case is actually realised in future reports.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Camurus on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this Camurus story leaves you leaning bullish but still unsure, now is a good time to review the figures yourself and pressure test the optimism. To see what those upbeat signals look like in detail, take a closer look at the 3 key rewards.

See What Else Is Out There Beyond Camurus

For all the strengths in Camurus's story, the recent margin slip, mixed valuation signals, and dependence on a narrow set of drugs leave some investors uncomfortable with the risk profile.

If those pressure points have you looking for steadier ground, now is a good time to review companies screened for stronger resilience through the 292 resilient stocks with low risk scores and see how they compare.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com